Omeros (OMER) Earns News Sentiment Rating of 0.16

News headlines about Omeros (NASDAQ:OMER) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Omeros earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8274398185944 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Omeros (OMER) traded up $0.12 during trading hours on Friday, hitting $11.12. 940,211 shares of the stock were exchanged, compared to its average volume of 1,309,986. The firm has a market cap of $531.15, a price-to-earnings ratio of -9.50 and a beta of 3.57. Omeros has a 12 month low of $8.36 and a 12 month high of $27.09. The company has a current ratio of 4.12, a quick ratio of 4.10 and a debt-to-equity ratio of -29.93.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). The firm had revenue of $13.76 million for the quarter, compared to the consensus estimate of $21.94 million. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.45) earnings per share. equities analysts forecast that Omeros will post -0.76 earnings per share for the current fiscal year.

A number of research analysts have issued reports on OMER shares. Bank of America boosted their target price on shares of Omeros from $2.44 to $4.00 in a research note on Wednesday, February 14th. ValuEngine lowered shares of Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Wedbush reissued an “outperform” rating and set a $47.00 target price on shares of Omeros in a research note on Tuesday, November 28th. Needham & Company LLC lowered shares of Omeros from a “buy” rating to a “hold” rating and set a $9.01 target price for the company. in a research note on Friday, March 2nd. Finally, HC Wainwright set a $30.00 target price on shares of Omeros and gave the company a “buy” rating in a research note on Tuesday, January 23rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $28.75.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Insider Buying and Selling by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with's FREE daily email newsletter.

Leave a Reply